Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Liver Cancer Clinical Trials

Review the liver cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 51-75 of 159

Tislelizumab Before and After Radiation Therapy for the Treatment of Liver Cancer
Status: Active
Location: 2 locations
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma after Liver Transplant
Status: Active
Location: 2 locations
Hypofractionated Radiotherapy Followed by Durvalumab with or without Tremelimumab for the Treatment of Liver Cancer
Status: Active
Location: 2 locations
Combination of TATE and PD-1 Inhibitor in Liver Cancer
Status: Active
Location: 2 locations
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Status: Active
Location: 2 locations
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Status: Active
Location: 2 locations
At-Home Cancer Directed Therapy versus in Clinic for the Treatment of Patients with Advanced Cancer, Cancer CARE Beyond Walls
Status: Active
Location: 2 locations
A Study of HB0045 Injection in Patients With Advanced Solid Tumors
Status: Active
Location: 2 locations
Treatment of Chimeric Antigen Receptor Expressing Autologous T Cells as Immunotherapy for Patients with Liver Cancer
Status: Active
Location: 2 locations
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor with Liver Metastatic Disease
Status: Active
Location: 2 locations
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
Status: Active
Location: 2 locations
Comparing Length of Treatment with Immunotherapy in Patients with Advanced Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Regorafenib and Yttrium-90 Transarterial Radioembolization for the Treatment of Unresectable Hepatocellular Cancer
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Radiation Treatment (Therasphere) in Combination with Systemic Therapy for the Treatment of Advanced Hepatocellular Carcinoma
Status: Active
Location: Northwestern University, Chicago, Illinois
Tremelimumab and Durvalumab for the Treatment of Advanced Liver Cell Cancer in Patients with Child-Pugh-B Cirrhosis
Status: Active
Location: Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas
Pembrolizumab in Combination with Gemcitabine and Cisplatin for Treating Patients with High-Risk Resectable Intrahepatic Cholangiocarcinoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined with Immune Checkpoint Inhibition after High-Dose External Beam Radiation Therapy in Treating Patients with Unresectable Liver Cancer
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Gemcitabine, Cisplatin, and Pembrolizumab before and after Surgery for the Treatment of Potentially Resectable Biliary Tract Cancer
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Enfortumab Vedotin for the Treatment of Patients with Unresectable or Metastatic Colorectal Cancer or Hepatocellular Carcinoma
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Sacituzumab Govitecan for the Treatment for Patients with Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma
Status: Active
Location: University of Kansas Cancer Center, Kansas City, Kansas
Immunotherapy with or without Radiation Therapy for the Treatment of Patients with Advanced Unresectable Intrahepatic Cholangiocarcinoma, a HYPERION CCA Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Cell Therapy (Tumor Infiltrating Lymphocytes) and Aldesleukin in Treating Patients with Locally Advanced, Recurrent, Refractory, or Metastatic Biliary Tract Cancers
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
Status: Active
Location: UC San Diego Moores Cancer Center, La Jolla, California
Ligufalimab and Cadonilimab for the Treatment of Advanced Hepatobiliary Cancers
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas